Minh Nhat le
Optometrist · San Jose, CANPI 1316936792
Payments from drug & device makers
Across 168 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$1K
- Oyster Point Pharma, Inc.$765
- Alcon$635
- Tarsus Pharmaceuticals, Inc.$614
- Sun Pharmaceutical Industries Inc.$501
- Amgen$418
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,36899%
- Gifts$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 17 | $1,243 |
| Oyster Point Pharma, Inc. | 25 | $765 |
| Alcon | 17 | $635 |
| Tarsus Pharmaceuticals, Inc. | 24 | $614 |
| Sun Pharmaceutical Industries Inc. | 15 | $501 |
| Amgen(2 entities) | 16 | $418 |
| Bausch & Lomb Americas Inc. | 7 | $310 |
| AbbVie(2 entities) | 5 | $307 |
| Kala Pharmaceuticals, Inc. | 19 | $287 |
| Novartis | 10 | $206 |
| Sight Sciences, Inc. | 2 | $168 |
| Omeros Corporation | 1 | $125 |
| Dompe US, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $125 |
| Genentech USA, Inc. | 1 | $124 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $123 |
| Astellas Pharma US Inc | 1 | $112 |
| Visioneering Technologies, Inc. | 1 | $96 |
| Carl Zeiss Meditec USA, Inc. | 1 | $63 |
| LKC Technologies, Inc. | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Carl Zeiss Meditec AG | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,402 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 97 | $92,087 |
| RestasisCyclosporine | 110 | $84,525 |
| Cyclosporine | 66 | $37,154 |
| TyrvayaVarenicline Tartrate | 31 | $29,665 |
| MieboPerfluorohexyloctane/Pf | 17 | $14,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $310 | $106,273114 claims |
| AbbVieRestasis | $307 | $84,525110 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $765 | $29,66531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in San Jose
- Vivian LookSan Jose$152K
- Meng LinBerkeley$6.9M
- Steve YoelinNewport Beach$6.1M
- Matthew GellerSpring Valley$3.5M
- David Kasanoffla Mesa$1M
- Colton HeinrichFullerton$987K
- Elsa PaoOakland$910K
- Keith WanSan Diego$887K
- Selena ChanSan Francisco$677K
- Melissa EricksonDavis$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.